Valuation: Santhera Pharmaceuticals Holding AG

Market Cap 215M 256M 231M 195M 366M 24.4B 368M 2.58B 1.01B 12.66B 963M 942M 40.73B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 235M 281M 252M 213M 401M 26.7B 403M 2.83B 1.1B 13.86B 1.05B 1.03B 44.58B EV / Sales 2026 *
2.49x
EV / Sales 2027 * 1.98x
Free-Float
84.85%
Yield 2026 *
-
Yield 2027 * -
1 day+2.34%
1 week-7.86%
Current month-9.29%
1 month-10.79%
3 months-6.89%
6 months-20.65%
Current year+11.59%
1 week 13.42
Extreme 13.42
14.62
1 month 13.42
Extreme 13.42
16.28
Current year 11.7
Extreme 11.7
18.84
1 year 9.57
Extreme 9.57
18.84
3 years 7.21
Extreme 7.21
18.84
5 years 5
Extreme 5
20.3
10 years 5
Extreme 5
820
Manager TitleAgeSince
Chief Executive Officer 50 15/07/2026
Director of Finance/CFO 51 24/02/2025
Chief Operating Officer 55 01/09/2022
Director TitleAgeSince
Chairman 64 30/06/2022
Director/Board Member 58 04/04/2017
Director/Board Member 47 27/06/2023
Date Insider Type Main position Quantity % Market Cap. Importance
22/01/24 Buy 30,228 0.2396%
06/07/23 Buy 2,000 0.0016%
11/01/22 Buy 30,000 0.0549%
Change 5-day change 1-year change 3-year change Capi.($)
+2.63%-7.86%+43.91%+58.33% 252M
+3.62%+1.68%+48.80%+96.02% 1,040B
+2.13%-1.76%+33.04%+61.18% 599B
+3.32%+4.47%+23.72%+92.54% 485B
+3.80%+3.21%+73.99%+41.51% 350B
+3.09%+6.03%+27.85%+45.42% 345B
+2.82%+4.68%+17.38%+40.15% 272B
+3.40%+2.86%-3.33%+12.08% 244B
+3.21%+3.15%+45.01%+48.53% 223B
+3.80%+4.56%+29.59%+93.86% 183B
Average +3.08%+1.12%+34.00%+58.96% 374.3B
Weighted average by Cap. +3.30%+2.31%+36.59%+67.74%

Financials

2026 *2027 *
Net sales 94.7M 113M 101M 85.83M 161M 10.74B 162M 1.14B 444M 5.57B 424M 415M 17.93B 116M 138M 124M 105M 197M 13.11B 198M 1.39B 541M 6.8B 517M 506M 21.88B
Net income - -
Net Debt 20.3M 24.19M 21.75M 18.4M 34.54M 2.3B 34.76M 244M 95.13M 1.19B 90.83M 88.87M 3.84B 13.4M 15.97M 14.36M 12.14M 22.8M 1.52B 22.94M 161M 62.79M 789M 59.96M 58.66M 2.54B
Projected Income Statement - Annual - Santhera Pharmaceuticals Holding AG
Logo Santhera Pharmaceuticals Holding AG
Santhera Pharmaceuticals Holding AG (Santhera) is a Switzerland-based company engaged in the pharmaceutical sector. The Company operates through one business segment, which is the research, development and commercialization of pharmaceutical products for the treatment of neuromuscular and mitochondrial diseases, such as Duchenne muscular dystrophy (DMD) and cystic fibrosis (CF). The Company focuses also on development of gene therapy for the treatment of LAMA2 (Laminin Subunit Alpha 2) deficient congenital muscular dystrophy (CMD). Santhera operates through its wholly owned subsidiaries: Santhera Pharmaceuticals (Schweiz) AG, Liestal, Santhera Pharmaceuticals (USA) Inc, Santhera Pharmaceuticals (Canada) Inc, Santhera Pharmaceutical (Deutschland) GmbH and Oy Santhera Pharmaceuticals (Finland) Ltd.
Employees
94
Date Price Change Volume
14/10/26 CHF 14.06 +2.63% 66,249
13/10/26 CHF 13.70 -6.04% 91,162
12/10/26 CHF 14.58 +2.10% 27,118
09/10/26 CHF 14.28 +0.99% 52,127
08/10/26 CHF 14.14 -3.68% 94,070
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Santhera Pharmaceuticals Holding AG
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
14.06CHF
Average target price
27.50CHF
Spread / Average Target
+95.59%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Santhera Pharmaceuticals Holding AG
  1. Stock Market
  2. Stocks
  3. SANN Stock